|
WKN: 896133 Ist von den Höchstständen (305€!) meilenweit entfernt und hat die Analysten nicht enttäuscht. INCYTE PHARMA LOSS BETTER THAN FIRST CALL VIEW BY 18 CENTS Vielleicht kommt ja eine neue Kaufempfehlung! Incyte posts narrower 2Q loss By Stephanie O`Brien, CBS.MarketWatch.com Last Update: 5:18 PM ET Jul 18, 2000 NewsWatch Latest headlines PALO ALTO, Calif. (CBS.MW) -- Incyte Genomics reported a narrower-than-expected second-quarter loss after the market closed on Tuesday. Separately, the company (INCY: news, msgs) announced a 2-for-1 stock split which will be paid as a stock dividend. Incyte reported a loss of $6.6 million, or 21 cents a share, compared with a loss of $7.4 million, or 26 cents in the same period a year ago. Revenue rose to $46 million from $37.9 million. Nine analysts surveyed by First Call had expected Incyte, which provides databases of full-length human genes, gene mapping, microbial gene sequences and animal genes, to lose 39 cents in the quarter. Shares on Tuesday fell 1 11/16 to 94 23/32. Incyte provides access to its database on a subscription basis. Its LifeSeq database links biological data with genetic information to help drug discovery. For the second quarter ending June 30, database and partnership program revenue rose to $35.6 million compared to $30.8 in the same period a year ago. Incyte said operating expenses rose to $60.4 million from $45.6 million in the year-ago quarter. |
|
| aus der Diskussion: | INCYTE - Aktiensplit sollte beflügeln! |
| Autor (Datum des Eintrages): | hanni55 (19.07.00 13:47:48) |
| Beitrag: | 1 von 3 (ID:1353537) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |